Can levosimendan reduce ECMO weaning failure in cardiogenic shock? A cohort study with propensity score analysis.
Background<br> Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock. ECMO weaning can, however, be challenging and lead to circulatory failure and death. Recent data suggest a potential benefit...
Main Authors: | Guilherme, E, Jacquet-Lagrèze, M, Pozzi, M, Achana, F, Armoiry, X, Fellahi, J-L |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2020
|
Similar Items
-
Correction to: Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis
by: Enrique Guilherme, et al.
Published: (2020-08-01) -
Levosimendan for VA‐ECMO weaning: the silver lining
by: Rasha Kaddoura, et al.
Published: (2022-02-01) -
Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock
by: Yu-Wen Chen, et al.
Published: (2022-06-01) -
VA‐ECMO weaning strategy using adjusted pulse pressure by vasoactive inotropic score in AMI complicated by cardiogenic shock
by: Bo Ram Lee, et al.
Published: (2024-10-01) -
Should ECMO be used in cardiogenic shock?
by: Orhan Gokalp, et al.
Published: (2019-05-01)